GlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival
June 20 2016 - 3:02AM
Dow Jones News
By Ian Walker
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) and
Innoviva Inc. (INVA) said Monday a study of a triple combination
therapy that mixes FF, UMEC and VI showed improved lung function
and health-related quality of life in patients with chronic
obstructive pulmonary disease, compared with rival treatment
Symbicort(R) Turbohaler(R).
Glaxo said the findings from the study, named 'fulfil,' support
its plans for an European Union regulatory submission of the
combination therapy by the end of 2016. It also plans to submit a
new drug application for the therapy to the U.S. Food and Drug
Administration by the end of 2016.
"We are delighted with the outcome of the fulfil study, which
marks a further step towards making this closed triple combination
therapy available to appropriate patients with COPD," Glaxo's head
of respiratory R&D Dave Allen said.
"Triple combination therapy is already a reality for many
patients with COPD and is dispensed in multiple inhalers. By
combining three medicines in a single inhaler we can offer a
convenient, once-daily dosing option to patients while improving
their symptoms," he said.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
June 20, 2016 02:47 ET (06:47 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
